- •Pelacarsen was studied in subjects of Japanese ancestry.
- •Single (20, 40, 80 mg) and multiple doses of pelacarsen 80 mg were used.
- •Maximal, placebo-corrected Lp(a) reduction was -106% with 80 mg monthly dose.
- •No serious adverse events were noted.
- •No clinically relevant abnormalities in any laboratory parameters were noted.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- NHLBI Working Group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis.J Am Coll Cardiol. 2018; 71: 177-192
- Structure, function, and genetics of lipoprotein(a).J Lipid Res. 2016; 57: 1339-1359
- Existing and emerging strategies to lower Lipoprotein(a).Atherosclerosis. 2022; 349: 110-122
- Emerging RNA therapeutics to lower blood levels of Lp(a): JACC Focus Seminar 2/4.J Am Coll Cardiol. 2021; 77: 1576-1589
- Lipoprotein(a) reduction in persons with cardiovascular disease.N Engl J Med. 2020; 382: 244-255
- Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a).Nat Med. 2022; 28: 96-103
- Single ascending dose study of a short interfering RNA targeting lipoprotein(a) production in individuals with elevated plasma lipoprotein(a) levels.JAMA. 2022; 327: 1679-1687
Assessing the impact of lipoprotein(a) lowering With TQJ230 on major cardiovascular events in patients with CVD - Lp(a HORIZON. https://clinicaltrials.gov/ct2/show/NCT04023552. 2019.
- Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study.Lancet. 2015; 386: 1472-1483
- Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.Lancet. 2016; 388: 2239-2253
- Studies on apolipoprotein(a) phenotypes. Part 1. Phenotype frequencies in a healthy Japanese population.Atherosclerosis. 1992; 96: 1-8
- Ancestry, lipoprotein(a), and cardiovascular risk thresholds: JACC Review Topic of the Week.J Am Coll Cardiol. 2022; 80: 934-946
- Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017.J Atheroscler Thromb. 2018; 25: 846-984
- Lipoprotein (a) measurements for clinical application.J Lipid Res. 2016; 57: 526-537
- Integrated assessment of the clinical performance of GalNAc3-conjugated 2’-O-methoxyethyl chimeric antisense oligonucleotides: I. Human volunteer experience.Nucleic Acid Ther. 2019; 29: 16-32
- Temporal variability in lipoprotein(a) levels in patients enrolled in the placebo arms of IONIS-APO(a)Rx and IONIS-APO(a)-LRx antisense oligonucleotide clinical trials.J Clin Lipidol. 2018; 12 (e122): 122-129
- 'LDL-C' = LDL-C + Lp(a)-C: implications of achieved ultra-low LDL-C levels in the proprotein convertase subtilisin/kexin type 9 era of potent LDL-C lowering.Curr Opin Lipidol. 2015; 26: 169-178
- Relationship between “LDL-C,” estimated true LDL-C, apolipoprotein B-100, and PCSK9 levels following lipoprotein(a) lowering with an antisense oligonucleotide.J Clin Lipidol. 2018; 12: 702-710
- Novel method for quantification of lipoprotein(a)-cholesterol: implications for improving accuracy of LDL-C measurements.J Lipid Res. 2021; 62100053
- Effect of pelacarsen on lipoprotein(a) cholesterol and corrected low-density lipoprotein cholesterol.J Am Coll Cardiol. 2022; 79: 1035-1046
- Antisense inhibition of apolipoprotein (a)</number> to lower plasma lipoprotein (a) levels in humans.J Lipid Res. 2016; 57: 340-351
- Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: A mendelian randomization analysis.JAMA Cardiol. 2018; 3: 619-627
- Estimation of the required lipoprotein(a)-lowering therapeutic effect size for reduction in coronary heart disease outcomes: A mendelian randomization analysis.JAMA Cardiol. 2019; 4: 575-579
- Lipoprotein(a)-lowering by 50 mg/dL (105 nmol/L) may be needed to reduce cardiovascular disease 20% in secondary prevention: a population-based study.Arterioscler Thromb Vasc Biol. 2020; 40: 255-266
- Impact of apolipoprotein(a) isoform size on lipoprotein(a) lowering in the HPS2-THRIVE Study.Circulation. Genomic and precision medicine. 2018; 11e001696
- Lipoprotein(a), PCSK9 Inhibition, and cardiovascular Risk.Circulation. 2019; 139: 1483-1492
- Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial.Eur Heart J. 2020; 41: 4245-4255
Publication stageIn Press Journal Pre-Proof
Author contributions: First manuscript draft (E K-P, ST), editing for critical content (EP-K, AL, ST), gathering of data (EP-K, AL), obtaining pharmacokinetic data (J-HY, EH, AH, and AM), and statistical analysis (SX).
Conflict of interest: EK-P and SX are employees of Ionis Pharmaceuticals, EH is former employee of Akcea Therapeutics. AL, J-HY, AH, and AM are employees of Novartis Pharma. ST is an employee of Ionis Pharmaceuticals and of the University of California San Diego and has received research support from the Fondation Leducq and NHLBI (R01HL159156). ST is a co-inventor and receives royalties from patents owned by UCSD on oxidation-specific antibodies and of biomarkers related to oxidized lipoproteins and are co-founder and have an equity interest in Oxitope, Inc and its affiliate, Kleanthi Diagnostics, LLC and Covicept Therapeutics. The terms of this arrangement have been reviewed and approved by the University of California San Diego in accordance with its conflict-of-interest policies.
Financial Support: This study was funded by Akcea Therapeutics.